Is it too late to buy rapid risers ARM Holdings plc, WPP plc ord 10p and Hikma Pharmaceuticals plc?

Edward Sheldon looks at whether it’s too late to buy fast movers ARM Holdings plc (LON: ARM), WPP plc ord 10p (LON: WPP) and Hikma Pharmaceuticals plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After the market-wide Brexit carnage on the morning of 24 June, I’ve been quite surprised by the rapid rebounds in many FTSE 100 stocks. Today I’m looking at three popular UK growth companies and examining whether it’s too late to jump on board these gravity defying stocks.

Tech king

After trading as low as 970p on 24 June, ARM Holdings (LSE: ARM) has spiked to 1,200p, a 24% gain.  At that price ARM is trading on a current P/E ratio of 49, which falls to 33 on next year’s earnings. Is that too much to pay?

While a P/E ratio of 49 might seem high, on a relative basis it’s actually low for ARM. The tech giant has traditionally traded on high multiples thanks to its impressive growth record, with its P/E ratio climbing as high as 143 in early 2014 and averaging 59 over the last 10 years on a quarterly basis.

While analysts have concerns over slowing smartphone growth, I believe the long term growth story is still intact at ARM. The company is broadening its revenue base to focus on networking, servers and the Internet of Things and these areas should offset any weakness in smartphone chip revenues.  

ARM has grown its earnings at an annualised rate of 29% over the last five years and with the city forecasting revenue growth of 20% and 13% for the next two years, long term investors should continue to be rewarded.

Blue sky territory

Advertising giant WPP (LSE: WPP) has rebounded 13% since its post Brexit lows and is now trading in blue sky territory, having surpassed its all-time highs set in April.

As advertising companies are often seen as proxies for global growth, I wasn’t expecting to see such a rise from WPP with the current economic uncertainty surrounding the UK and Europe. However WPP has strong exposure to the US and fast growing emerging markets, and this has clearly appealed to investors.

As a WPP shareholder I’m not complaining about the stock’s recent performance as the company has been one of the better performers in my portfolio since I bought it, showing gains of almost 30% in less than a year. But would I buy more WPP shares at the current price?

Trading on a P/E ratio of 15 times next year’s earnings, WPP doesn’t look particularly expensive, however looking at the share price chart it’s clear to see that it’s prone to peaks and troughs. For this reason, I’ll be waiting for another dip in the share price before I add to my position.

Fast gains

Hikma Pharmaceuticals (LSE: HIK) has been on my watch list for a while now and I’m kicking myself that I didn’t buy a small position during the Brexit chaos as the stock has risen an incredible 38% since then.

I’m very bullish on the long-term prospects for Hikma as after acquiring Bedford Laboratories and Roxane Laboratories in the last two years, the healthcare company is poised to launch many new drugs in the near future. Furthermore, with a high proportion of its sales in the US, Hikma should benefit from weaker sterling.

However, as with WPP, I’ll be waiting for a pullback before buying-in. Patience is everything in this game and I’m sure there will be a better opportunity to buy Hikma in the future at a lower price.

Edward Sheldon owns shares in WPP. The Motley Fool UK has recommended ARM Holdings and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »